Companies / Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc.
APLSCIK 1492422WALTHAM, MA
Financials · FY2025
Ownership
128.0M shares outstanding · as of Apr 30, 2026
Ownership
| Insiders | 2.77% | 3,550,719 |
| 10%+ / strategic | 10.33% | 13,228,073 |
| Institutions | 104.59% | 133,897,030 |
| Public float | 0.00% | 0 |
Reported holdings exceed shares outstanding — public float shown as 0; some positions may overlap or lag.
% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.
Insiders 18
View all →| Insider | % of shares | Shares |
|---|---|---|
Deschatelets PascalChief Scientific Officer | 0.92% | 1,177,222 |
Francois CedricCEOChief Executive Officer · Director | 0.62% | 798,783 |
Machiels AlecDirector | 0.30% | 384,989 |
Dunlop A. SinclairDirector | 0.13% | 161,567 |
Sullivan Timothy EugeneChief Financial Officer | 0.12% | 152,041 |
Watson David O.General Counsel | 0.11% | 144,517 |
Boucher KelleyChief People Officer | 0.10% | 127,804 |
Nicholson NurChief Technical Officer | 0.09% | 116,338 |
DeLong Mark JeffreyChief Business & Strat Officer | 0.09% | 114,591 |
Meltzer LeslieChief Research and Development | 0.08% | 107,024 |
Institutional holders 311
View all →| Holder | Value | % of shares |
|---|---|---|
| $319.56M | 9.94% | |
| $307.02M | 9.55% | |
| $268.15M | 8.34% | |
| $230.43M | 7.17% | |
| $194.68M | 6.05% | |
| $192.59M | 5.99% | |
| $157.25M | 4.89% | |
| $142.82M | 2.77% | |
| $115.89M | 3.60% | |
| $105.16M | 3.27% |
Activity
Mar 31, 2026View all →
InsidersInstitutions
Who's accumulating and trimming this stock (13F).| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Q2 2026 as of | BlackRock, Inc. 13F manager | Exit | Common stock | $-157.25M | -6.3M -100.00% | 0 | high |
| Q1 2026 as of | Hbk Investments L P 13F manager | New | Common stock | $142.82M | +3.5M | 3,550,000 2.77% of shares | high |
| Q2 2026 as of | State Street Corporation 13F manager | Exit | Common stock | $-115.89M | -4.6M -100.00% | 0 | high |
| Q1 2026 as of | Balyasny Asset Management L.P. 13F manager | Add | Common stock | $74.52M | +1.9M +2843.98% | 1,917,501 1.50% of shares | high |
| Q1 2026 as of | AQR Capital Management, LLC 13F manager | Trim | Common stock | $-74.37M | -1.8M -81.20% | 427,970 0.33% of shares | high |
| Q1 2026 as of | Orbimed Advisors LLC 13F manager | Exit | Common stock | $-61.04M | -2.4M -100.00% | 0 | high |
| Q1 2026 as of | Millennium Management LLC 13F manager | Add | Common stock | $52.72M | +1.3M +138.45% | 2,256,802 1.76% of shares | high |
| Q1 2026 as of | TIG Advisors, LLC 13F manager | New | Common stock | $50.41M | +1.3M | 1,252,986 0.98% of shares | high |
5%+ ownership events
Schedule 13D / 13G
| Filer | Stance | % of class |
|---|---|---|
| Vanguard Group Inc | Passive13G/A | — |
| BlackRock, Inc. | Passive13G | — |
| RTW Investments, LP | Passive13G | — |
Securities
via CUSIP / OpenFIGI
| Symbol | Type | CUSIP |
|---|---|---|
| APLS | — | 03753U106 |